Humanwell Healthcare (Group) Co.,Ltd. (SHA:600079)

China flag China · Delayed Price · Currency is CNY
21.08
+0.15 (0.72%)
Sep 30, 2025, 3:00 PM CST
0.72%
Market Cap34.41B
Revenue (ttm)24.64B
Net Income (ttm)1.37B
Shares Out1.63B
EPS (ttm)0.85
PE Ratio24.83
Forward PEn/a
Dividend0.47 (2.23%)
Ex-Dividend DateAug 19, 2025
Volume16,091,497
Average Volume42,408,098
Open20.96
Previous Close20.93
Day's Range20.89 - 21.19
52-Week Range19.37 - 25.90
Beta0.46
RSI43.79
Earnings DateOct 28, 2025

About SHA:600079

Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection for endotracheal intubation, and general anesthesia using artificial respiration; remifentanil hydrochloride for Injection for induction and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for patients requiring opioid analgesia; nabuphine hydrochloride injection for induction of anesthesia; alfentanil hydrochloride injectio... [Read more]

Sector Healthcare
Founded 1993
Employees 17,650
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600079
Full Company Profile

Financial Performance

In 2024, SHA:600079's revenue was 25.44 billion, an increase of 3.71% compared to the previous year's 24.52 billion. Earnings were 1.33 billion, a decrease of -37.70%.

Financial Statements

News

There is no news available yet.